Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

38.92 -0.63 (-1.59%)
Streaming Delayed Price Updated: 1:30 PM EDT, Oct 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast
 
Via Benzinga
Earnings Scheduled For May 12, 2025
 
Via Benzinga
What to Expect from Xenon Pharmaceuticals's Earnings
 
Via Benzinga
Xenon Reports Second Quarter 2025 Financial Results & Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Report Q2 2025 Financial Results on August 11, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Earnings Scheduled For August 11, 2025
 
Via Benzinga
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
Xenon Joins the Russell 3000® and Russell 2000® Indexes
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications 
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Crude Oil Gains 3%; US Inflation Eases In April
 
Via Benzinga
Topics Economy
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
This Discover Financial Services Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Xenon to Report Q1 2025 Financial Results on May 12, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Present at Stifel 2025 Virtual CNS Forum
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Outlines Key Corporate Milestone Opportunities for 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.